Low Level Laser Therapy (LLLT) for the Treatment of Hand Osteoarthritis.
Launched by DAVID MOSS · Dec 30, 2020
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of Low Level Laser Therapy (LLLT) on people with hand osteoarthritis, a condition that causes pain, stiffness, and swelling in the joints of the hands. Participants in the study will be randomly assigned to receive either the real laser treatment or a placebo (sham) treatment for six weeks. During this time, they will visit the clinic weekly to rate their pain and assess how well they can use their hands. After the treatment period, there will be a follow-up visit six weeks later to evaluate their pain and hand function again.
To participate, individuals must be at least 18 years old and receive care at Nellis Air Force Base. They should have hand pain along with specific signs of osteoarthritis, such as joint enlargement or deformities in certain joints. However, people with other types of arthritis, recent surgeries, or fractures in the hand are not eligible. This study is important because it may help determine if LLLT can effectively relieve pain and improve function for those suffering from hand osteoarthritis.
Gender
ALL
Eligibility criteria
- • \*\*Patients must be able to get care at Nellis Air Force Base (a military installation) in order to participate in this study\*\*
- Inclusion Criteria:
- • Male and Female Active Duty and DoD Beneficiaries aged 18 years or older
- • Hand pain, aching, or stiffness
- And at least 3 of the 4 following features:
- • Hard tissue enlargement of 2 or more of 10 selected joints
- • Hard tissue enlargement of 2 or more distal interphalangeal (DIP) joints
- • Fewer than 3 swollen metacarpophalangeal (MCP) joints
- • Deformity of at least 1 of 10 selected joints
- • (The 10 selected joints are the first carpometacarpal (CMC), second and third proximal interphalangeal (PIP), second and third DIP joints of both hands.)
- Exclusion Criteria:
- • Known diagnosis of another type of arthritis: rheumatoid, psoriatic, crystalline, inflammatory bowel associated arthritis
- • History of treatment with LLLT in the past 12 weeks Surgery within the past 6 weeks
- • Hand fracture within the past 6 weeks
- • Pregnancy
About David Moss
David Moss is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a strong focus on innovation and ethical practices, Moss facilitates the development of groundbreaking therapies across various therapeutic areas. By fostering collaboration among researchers, healthcare professionals, and regulatory bodies, he ensures that clinical trials are conducted with the highest standards of integrity and scientific rigor. David Moss's leadership and vision aim to bridge the gap between scientific discovery and practical application, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nellis Air Force Base, Nevada, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials